Hs-cTnT and hs-cTnI are the most important biomarkers used in the acute CAD setting [acute myocardial infarction (AMI)]16 but are still not an established part of the routine clinical diagnostics in the setting of the chronic coronary syndrome.1 However, pilot studies have indicated possible diagnostic and prognostic value of hs-cTnT and hs-cTnI for CAD and major cardiac adverse events (MACE).13–15,17,18. This evidence concerns the gene TNNI3 and acute myocardial infarction.